Imuran
(Azathioprine)ApprovedSmall molecule
Azathioprine is an immunosuppressant drug used to prevent the body's immune system from rejecting transplanted organs and to treat autoimmune diseases like rheumatoid arthritis and certain inflammatory bowel conditions.[2] Imuran is currently approved and in use across 43 indications[4].[1]
Imuran is one of 745 small molecule programs targeting Liver Transplant. It is currently in Approved.
43
Indications
101
Total Trials
20
Active Trials
744
Competitors
2
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 43 indications
Competition
Competitive Landscape
255 competitors in Acute Myeloid Leukemia
#DrugCompanyPhaseTrials
1Imuran
LLegacy Health System
Approved
Xospata
AstellasPhase 3
Fludara
SanofiPhase 3
Mylotarg
WWyeth-Lederle Vaccines
Phase 3
Cerubidine
EEastern Cooperative Oncology Group
Phase 3
Vepesid
AAvyxa
Phase 3
Vanflyta
Daiichi SankyoPhase 3
Cerubidine
HHikma Pharmaceuticals LLC
Phase 3
Cellcept
RochePhase 3
Trexall
Jazz PharmaceuticalsPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Crohn's Disease10 trials
HLADQA1*05 Genotype and the Efficacy of Treatment With Infliximab in Chinese Population Crohn's Disease
Not yet recruiting·SSixth Affiliated Hospital, Sun Yat-sen University·Phase 4·NCT05813860·976 enrolled
Show 7 more trials
Preventing Postoperative Relapse in Crohn's Disease Patients at Risk: Azathioprine Versus Mesalazine
Completed·—·Phase 3·NCT00946946·78 enrolled
Lupus Nephritis10 trials
Show 7 more trials
Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00774852·137 enrolled
Ulcerative Colitis9 trials
Show 6 more trials
Vasculitis7 trials
Rituximab Vasculitis Maintenance Study
Completed·—·Phase 3·NCT01697267·188 enrolled
Show 4 more trials
52 more indications
Rheumatoid Arthritis3 trials
Neuromyelitis Optica3 trials
Microscopic Polyangiitis2 trials
Transplantation2 trials
ANCA-Associated Vasculitis2 trials
Systemic Lupus Erythematosus2 trials
Adalimumab2 trials
Myasthenia Gravis2 trials
Safety and Efficacy1 trial
Lupus1 trial
Dermatitis1 trial
Colitis1 trial
Randomized Controlled Trial1 trial
A proSpective Randomized Controlled Trial comParing infliximAb-antimetabolites Combination Therapy to Anti-metabolites monotheRapy and Infliximab monothErapy in Crohn's Disease Patients in Sustained Steroid-free Remission on Combination Therapy
Completed·GGroupe d'Etude Therapeutique des Affections Inflammatoires Digestives·Phase 4·NCT02177071·211 enrolled
Renal Transplant Rejection1 trial
Crohn's Diseases1 trial
Immune Thrombocytopenia1 trial
Reposition of Second Line Treatment in Chronic Immune Thrombocytopenia
Completed·—·Phase 4·NCT03229746·40 enrolled
Alopecia Areata1 trial
Cardiomyopathy1 trial
Advanced1 trial
Steroids and Azathioprine in Advanced IgAN
Completed·—·Phase 3·NCT01392833·46 enrolled
Adverse Effect1 trial
Moderate to Severe Crohn's Disease1 trial
Skin Cancer1 trial
Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol
Terminated·—·Phase 4·NCT00866684·44 enrolled
Stem Cell Transplant1 trial
Tolerance1 trial
Pemphigus Vulgaris1 trial
Inflammatory Disease1 trial
Churg-Strauss syndrome1 trial
Vitiligo1 trial
Crohn's Disease (CD)1 trial
Relapsing Polychondritis1 trial
Infertility1 trial
Sickle Cell Disease1 trial
Kidney1 trial
Rheumatic Disease1 trial
Chrohn's Disease1 trial
Unspecified1 trial
Regulatory
FDA Approval Timeline[5]
Jan 1, 1982
IMURAN
NDA NDA017391
Jan 1, 1982
IMURAN
NDA NDA016324
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Imuran drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Azathioprine. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Amidophosphoribosyltransferase Inhibitor[3]
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company
- LLegacy Health System